Where there is unmet clinical need, opportunities to develop therapeutics to help the greatest number of patients follow. It is important that the surrounding ecosystem directs biopharmaceutical companies and investors to respond to unmet need; however, legislative, and regulatory policies must align to ensure investments best support what patients want. This discussion will look at how the system is working and where fixes are needed to support biomedical advances in cancer and rare diseases.